Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination With Chlorambucil, Acalabrutinib (ACP-196) in Combination With Obinutuzumab, and Acalabrutinib Monotherapy in Subjects With Previously Untreated CLL
Brief Summary: This Primary objective is evaluating the efficacy of obinutuzumab in combination with chlorambucil (Arm A) compared with acalabrutinib in combination with obinutuzumab (Arm B) for the treatment of previously untreated chronic lymphocytic leukemia (CLL). Secondary objectives: 1) To evaluate the efficacy of obinutuzumab in combination with chlorambucil (Arm A) versus acalabrutinib monotherapy (Arm C) based on IRC assessment of PFS per IWCLL 2008 criteria.

2)To compare obinutuzumab plus chlorambucil (Arm A) versus acalabrutinib plus obinutuzumab (Arm B) and obinutuzumab plus chlorambucil (Arm A) versus acalabrutinib monotherapy (Arm C) in terms of: IRC-assessed objective response rate (ORR); Tine to next treatment (TTNT); Overall Survival (OS)


Options:
A: Arm Label: Arm A - Obinutuzumab in Combination with Chlorambucil; Type: ACTIVE_COMPARATOR; Interventions: Drug: Obinutuzumab, Drug: Chlorambucil | Arm Label: Arm B - Acalabrutinib in Combination with Obinutuzumab; Type: EXPERIMENTAL; Interventions: Drug: Acalabrutinib, Drug: Obinutuzumab | Arm Label: Arm C - Acalabrutinib Monotherapy; Type: EXPERIMENTAL; Interventions: Drug: Acalabrutinib | Intervention Type: DRUG; Name: Acalabrutinib; Assigned to Arm(s): Arm B - Acalabrutinib in Combination with Obinutuzumab, Arm C - Acalabrutinib Monotherapy | Intervention Type: DRUG; Name: Obinutuzumab; Assigned to Arm(s): Arm A - Obinutuzumab in Combination with Chlorambucil, Arm B - Acalabrutinib in Combination with Obinutuzumab | Intervention Type: DRUG; Name: Chlorambucil; Assigned to Arm(s): Arm A - Obinutuzumab in Combination with Chlorambucil
B: Arm Label: Safety Run-in Obinutuzumab + Venetoclax; Type: EXPERIMENTAL; Interventions: Drug: Venetoclax, Drug: Obinutuzumab | Arm Label: Obinutuzumab + Chlorambucil; Type: EXPERIMENTAL; Interventions: Drug: Chlorambucil, Drug: Obinutuzumab | Arm Label: Obinutuzumab + Venetoclax; Type: EXPERIMENTAL; Interventions: Drug: Venetoclax, Drug: Obinutuzumab | Intervention Type: DRUG; Name: Chlorambucil; Assigned to Arm(s): Obinutuzumab + Chlorambucil | Intervention Type: DRUG; Name: Venetoclax; Assigned to Arm(s): Obinutuzumab + Venetoclax, Safety Run-in Obinutuzumab + Venetoclax | Intervention Type: DRUG; Name: Obinutuzumab; Assigned to Arm(s): Obinutuzumab + Chlorambucil, Obinutuzumab + Venetoclax, Safety Run-in Obinutuzumab + Venetoclax
C: Arm Label: Fludarabine+Cyclophosphamide+Rituximab (FCR); Type: EXPERIMENTAL; Interventions: Drug: Rituximab, Drug: Cyclophosphamide, Drug: Fludarabine Phosphate | Arm Label: Fludarabine+Cyclophosphamide (FC); Type: ACTIVE_COMPARATOR; Interventions: Drug: Cyclophosphamide, Drug: Fludarabine Phosphate | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Fludarabine+Cyclophosphamide+Rituximab (FCR) | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Fludarabine+Cyclophosphamide (FC), Fludarabine+Cyclophosphamide+Rituximab (FCR) | Intervention Type: DRUG; Name: Fludarabine Phosphate; Assigned to Arm(s): Fludarabine+Cyclophosphamide (FC), Fludarabine+Cyclophosphamide+Rituximab (FCR)
D: Arm Label: Ibrutinib; Type: EXPERIMENTAL; Interventions: Drug: Ibrutinib | Arm Label: Chlorambucil; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chlorambucil | Intervention Type: DRUG; Name: Ibrutinib; Assigned to Arm(s): Ibrutinib | Intervention Type: DRUG; Name: Chlorambucil; Assigned to Arm(s): Chlorambucil

Answer: A